Shaping the next generation of life-saving drugs with precision medicine
When it comes to disease monitoring and prevention, research has historically focused on broad populations and statistical averages.
Based in Montreal, Quebec, CellCarta is on a mission to create a more customized approach to care and a healthier tomorrow with cutting-edge precision medicine. Bringing together a unique combination of biomarker experts from coast to coast, CellCarta delivers custom testing solutions and end-to-end sample measurement services specialized in immune monitoring, histopathology, proteomics, and genomics.
How they’re changing the game
Transcript
Narration: Canadian businesses are the building blocks of our economy and communities across Canada. So how do we help them go further, faster?
[A number of purple hexagons, of all different sizes, appear on screen. The hexagons come together to form a map of Canada.]
Text on screen: Global Hypergrowth Project
Narration: The Global Hypergrowth Project is a scale-up initiative that’s going to take eight of Canada’s most promising home-grown companies and help put their global growth into hyperdrive, while also creating new and innovative pathways for other emerging Canadian companies.
[Larger, purple-outlined white hexagons appear and disappear, moving from left to right across the screen. Each time a hexagon appears, it contains a symbol, different from the last, representing a Canadian industry, such as pharmacare, healthcare, AI, and manufacturing.]
[The camera zooms out and purple hexagons now form a map of the world. Eight large hexagons appear on top of the map, each containing the logo of a Canadian company participating in the Global Hypergrowth Project: Clio, Ada, Duchesnay Pharmaceutical Group, AlayaCare, Lightspeed, CellCarta, Vive Crop Protection, and Clarius.]
Narration: Now let’s meet one of these game-changing Canadian businesses.
[A hexagon with the CellCarta logo comes to the foreground, while all the other hexagons containing logos disappear. The logo contains two small black rectangles and two black squares with the name CellCarta underneath, on a white background.]
Narration: Based in Montreal, Quebec, CellCarta Biosciences is an expert in precision medicine, propelling it forward to ultimately provide Canadians with quicker access to more effective, personalized treatments, especially in the fields of oncology, and vaccine development.
[Scientists in a lab are using pipettes to drop liquid into test tubes on a counter.]
[A person in a lab coat is working at a desk, filling out forms on a clipboard.]
[Martin LeBlanc, Co-founder & Vice-chairman, CellCarta appears on screen. He is wearing a dress shirt and suit jacket, standing next to a large floor-to-ceiling window.]
Narration: We analyze blood samples collected in clinical trials worldwide and help pharmaceutical and biotech companies that are developing innovative drugs, zone-in on the patient populations that are going to have a positive response from the drug…
Narration: …and thereby, avoiding making those drugs prescribed [to] people [on whom they] will not have an effect.
Text on screen: How does CellCarta benefit Canada?
[A scientific laboratory technician inserts some test tube vials into a machine, and then interacts with a display monitor attached to the machine.]
[Martin LeBlanc reappears on the right side of the screen. On the left side of the screen, a bulleted list of items—appearing one by one—highlights the key messages he’s giving.]
Narration: The main benefits, I think, for Canada is that we are in a very innovative ecosystem and we have now become a global leader…
Narration: …but at the same time continuing to grow our base of operations in Montreal and in Dartmouth, Nova Scotia. So I think that having a life sciences leader, a global leader in a field that is highly important, that can lead to more effective and efficient drug development is an important strategic lever for patients, for the health care system and for the Canadian economy to encourage companies like ours to continue to grow in Canada.
Text on screen: How can the Global Hypergrowth Project help?
Narration: The strategic priorities working with GHP is to make sure that CellCarta continues to have a very strong anchoring in Canada to better identify and help us navigate the federal system and how certain types of programs for...
[Two laboratory technicians are looking at a monitor on the countertop in front of them, while one of them is using a keyboard.]
[A woman seated at a desk is looking at a computer monitor that is displaying several monochromatic diagrams, images and data.]
[Aerial footage of the city of Montreal, including office buildings in the downtown area.]
[A scientist wearing a lab coat and safety glasses is interacting with a large machine in front of her]
[Martin LeBlanc reappears on screen]
Narration: …companies of our size can help us to better make the case and make decisions about innovation and investing in Canada to continue our growth here versus elsewhere, where we have operations, is vitally important to us at this stage of our growth journey.
[A scientist in a lab is looking at a tablet]
Text on screen: CellCarta
Shaping the next generation of life-saving drugs
Narration: GHP is helping CellCarta take their growth to the next level. Because when Canadian businesses like CellCarta succeed, we all benefit.
[The hexagon with the CellCarta logo appears on the right side of the screen over top of the map of Canada made up of small faded-purple hexagons.]
[An animated purple line appears, forming the outline of a maple leaf. Once the outline is complete, the maple leaf turns purple and zooms in until the entire screen is purple.]
Narration: Follow their journey at canada.ca/hypergrowth
Text on screen: canada.ca/hypergrowth
CellCarta uses its research and technology to map the differences between tissues and cells, and ultimately, between individuals. By exploring these cellular differences, they can identify the biomarkers—the unique genetic, biological, and environmental factors that influence and can predict how a given patient responds to treatment and develops diseases—resulting in more targeted therapies and accurate solutions.
CellCarta’s innovative biomarker testing solutions enable a more proactive approach to care. They improve the customization of disease detection and prevention strategies, and foster more targeted therapies. From discovery to late-stage clinical trials, CellCarta’s comprehensive testing, biomarker research, and integrated laboratory services are helping to map a healthier future for all.
With support from GHP, CellCarta is looking to fast-track its goal of becoming the global partner of choice for biopharmaceutical companies seeking precision medicine solutions. Using precise, personalized medicine, CellCarta is contributing to the next generation of life-saving drugs.